Diltiazem in the treatment of calcinosis in juvenile dermatomyositis.

Autor: Bertorini TE; From the Departments of Neurology, daggerRadiology, double daggerMedicine, and section signPediatrics, The University of Tennessce Memphis, paragraph signMethodist Hospitals of Memphis, and paragraph signThe Memphis Neurosciences Center, Memphis, Tennessee., Sebes JI, Palmieri GM, Igarashi M, Horner LH
Jazyk: angličtina
Zdroj: Journal of clinical neuromuscular disease [J Clin Neuromuscul Dis] 2001 Jun; Vol. 2 (4), pp. 191-3.
DOI: 10.1097/00131402-200106000-00005
Abstrakt: Subcutaneous calcifications occur in a variety of diseases, including juvenile dermatomyositis. These calcifications cause disabling symptoms that do not always respond to immunosuppressant therapy. The calcium antagonist diltiazem reduces subcutaneous calcifications in CREST syndrome and in isolated cases of children with dermatomyositis. Our study was performed to determine the effects of diltiazem when used as adjunctive therapy in children with dermatomyositis.
Databáze: MEDLINE